SV2006002134A - Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis ref. 5195-sv - Google Patents

Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis ref. 5195-sv

Info

Publication number
SV2006002134A
SV2006002134A SV2005002134A SV2005002134A SV2006002134A SV 2006002134 A SV2006002134 A SV 2006002134A SV 2005002134 A SV2005002134 A SV 2005002134A SV 2005002134 A SV2005002134 A SV 2005002134A SV 2006002134 A SV2006002134 A SV 2006002134A
Authority
SV
El Salvador
Prior art keywords
pirrolotriazine
angiogenesis
ref
derivatives
diseases associated
Prior art date
Application number
SV2005002134A
Other languages
English (en)
Inventor
Catherine Brennan
Karl Miranda
Brent Chandler
Julie A Dixon
Barton Phillips
Jianmei Fan
Michael Brands
Andrea Mcclure
Benjamin Jones
Wenlang Fu
Donald Bierer
Steven Magnuson
Harold C E Kluender
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2006002134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of SV2006002134A publication Critical patent/SV2006002134A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS CON ESTRUCTURA DE PIRROLOTRIAZINA, A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES COMPUESTOS Y AL USO DE ESOS COMPUESTOS Y COMPOSICIONES PARA LA PREVENCION Y/O TRATAMIENTO DE TRASTORNOS HIPER-PROLIFERATIVOS Y ENFERMEDADES ASOCIADAS CON LA ANGIOGENESIS
SV2005002134A 2004-06-03 2005-06-03 Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis ref. 5195-sv SV2006002134A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57665204P 2004-06-03 2004-06-03
US62653104P 2004-11-09 2004-11-09

Publications (1)

Publication Number Publication Date
SV2006002134A true SV2006002134A (es) 2006-10-04

Family

ID=34971944

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002134A SV2006002134A (es) 2004-06-03 2005-06-03 Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis ref. 5195-sv

Country Status (31)

Country Link
US (3) US7563791B2 (es)
EP (1) EP1765823B1 (es)
JP (1) JP4958772B2 (es)
KR (1) KR101235602B1 (es)
CN (1) CN1993361B (es)
AR (1) AR049138A1 (es)
AT (1) ATE462708T1 (es)
AU (1) AU2005252217B2 (es)
BR (1) BRPI0510848A (es)
CA (1) CA2569396C (es)
DE (1) DE602005020293D1 (es)
EC (1) ECSP067043A (es)
ES (1) ES2342722T3 (es)
GT (1) GT200500137A (es)
HK (1) HK1109141A1 (es)
HN (1) HN2005000255A (es)
IL (1) IL179264A0 (es)
MA (1) MA28689B1 (es)
MX (1) MX279139B (es)
MY (1) MY145077A (es)
NO (1) NO20070049L (es)
NZ (1) NZ551742A (es)
PE (1) PE20060243A1 (es)
PH (1) PH12006502386B1 (es)
RU (1) RU2401269C2 (es)
SG (1) SG127661A1 (es)
SV (1) SV2006002134A (es)
TW (1) TW200608979A (es)
UY (1) UY28931A1 (es)
WO (1) WO2005121147A1 (es)
ZA (1) ZA200700011B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AU2006320440B2 (en) * 2005-12-02 2012-04-05 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP1976847B1 (en) 2005-12-21 2015-06-17 Novartis AG Pyrimidinyl aryl urea derivatives being fgf inhibitors
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
US7912582B1 (en) * 2007-05-03 2011-03-22 Innovation Associates, Inc. Robotic prescription filling system
KR101553211B1 (ko) 2007-09-10 2015-09-15 씨아이피엘에이 엘티디. Ｒａｆ 키나아제 저해제의 제조방법 및 상기 제조방법에 사용되는 중간체
EP2203060A4 (en) * 2007-09-25 2010-12-22 Bayer Healthcare Llc PYRROLOTRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER BY INHIBITING AURORA KINASE
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
CN103929961A (zh) * 2011-06-20 2014-07-16 美国阿尔茨海默病研究所公司 化合物及其治疗应用
AP3529A (en) 2011-07-01 2016-01-11 Bayer Ip Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
JP6047582B2 (ja) * 2011-12-15 2016-12-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換ベンゾチエニル−ピロロトリアジンおよび癌の処置におけるその使用
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
PE20170303A1 (es) * 2014-06-17 2017-04-19 Chiesi Farm Spa Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
AU2016378723B2 (en) 2015-12-22 2021-09-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CA3016161A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
JP7034084B2 (ja) * 2016-03-28 2022-03-11 インサイト・コーポレイション Ｔａｍ阻害剤としてのピロロトリアジン化合物
WO2018161033A1 (en) * 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
IL310023A (en) 2017-06-21 2024-03-01 SHY Therapeutics LLC Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases
TWI821200B (zh) 2017-09-27 2023-11-11 美商英塞特公司 Tam抑制劑之鹽
MX2021000127A (es) 2018-06-29 2021-03-29 Incyte Corp Formulaciones de un inhibidor de axl/mer.
CN114040760A (zh) 2018-12-31 2022-02-11 拜欧米富士恩公司 Menin-mll相互作用的不可逆抑制剂
EP3906029A4 (en) 2018-12-31 2022-09-21 Biomea Fusion, LLC INHIBITORS OF MENIN-MLL INTERACTION
JP2022533570A (ja) * 2019-05-13 2022-07-25 リレー セラピューティクス， インコーポレイテッド Ｆｇｆｒ阻害剤およびそれらの使用
KR20220062366A (ko) 2019-09-26 2022-05-16 센젠 타겟알엑스, 아이엔씨. 치환된 방향족 융합 고리 유도체, 및 이를 포함하는 조성물, 및 이의 용도
JP2023533771A (ja) * 2020-07-10 2023-08-04 ベイジン ファインドキュア バイオサイエンシーズ リミテッド トリアジン系化合物およびその組成物と用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770377B2 (en) * 1999-05-21 2004-02-19 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
KR100847605B1 (ko) * 2000-11-17 2008-07-21 브리스톨-마이어스스퀴브컴파니 ｐ38 키나제 관련 질병의 치료 방법 및 키나제 억제제로서유용한 피롤로트리아진 화합물
AU2003265349A1 (en) * 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7405213B2 (en) 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AU2006320440B2 (en) * 2005-12-02 2012-04-05 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP2203060A4 (en) * 2007-09-25 2010-12-22 Bayer Healthcare Llc PYRROLOTRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER BY INHIBITING AURORA KINASE

Also Published As

Publication number Publication date
US20130225809A1 (en) 2013-08-29
HK1109141A1 (en) 2008-05-30
GT200500137A (es) 2006-05-18
BRPI0510848A (pt) 2007-11-27
RU2401269C2 (ru) 2010-10-10
TW200608979A (en) 2006-03-16
CA2569396C (en) 2011-12-20
KR101235602B1 (ko) 2013-02-21
PE20060243A1 (es) 2006-04-21
SG127661A1 (en) 2007-01-30
AU2005252217B2 (en) 2011-05-12
CN1993361A (zh) 2007-07-04
WO2005121147A1 (en) 2005-12-22
AR049138A1 (es) 2006-06-28
ATE462708T1 (de) 2010-04-15
US20070208013A1 (en) 2007-09-06
ZA200700011B (en) 2008-11-26
JP2008501703A (ja) 2008-01-24
US7563791B2 (en) 2009-07-21
UY28931A1 (es) 2005-12-30
MX279139B (es) 2010-09-21
CA2569396A1 (en) 2005-12-22
IL179264A0 (en) 2007-03-08
PH12006502386B1 (en) 2010-12-23
DE602005020293D1 (de) 2010-05-12
NZ551742A (en) 2010-08-27
ES2342722T3 (es) 2010-07-13
EP1765823B1 (en) 2010-03-31
NO20070049L (no) 2007-01-30
MXPA06013457A (es) 2007-03-01
US8338595B2 (en) 2012-12-25
MA28689B1 (fr) 2007-06-01
EP1765823A1 (en) 2007-03-28
AU2005252217A1 (en) 2005-12-22
JP4958772B2 (ja) 2012-06-20
KR20070035028A (ko) 2007-03-29
HN2005000255A (es) 2010-09-17
CN1993361B (zh) 2010-05-26
RU2006147237A (ru) 2008-07-20
US20100075958A1 (en) 2010-03-25
ECSP067043A (es) 2006-12-29
MY145077A (en) 2011-12-15

Similar Documents

Publication Publication Date Title
SV2006002134A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis ref. 5195-sv
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
TW200602330A (en) Compounds and compositions as PPAR modulators
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
CL2008003780A1 (es) Compuestos derivados de azetidinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento o la prevencion de trastornos psiquiatricos, dependencia o deshabituacion a una sustancia, trastornos cognitivos, enfermedades neurodegenerativas, entre otras.
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
HN2003000104A (es) Derivados de ciclopenteno
AR073086A1 (es) Composicion farmaceutica para el tratamiento de un trastorno de ansiedad que comprende exo-7-(8-h-8-aza-biciclo(3,2,1)oct-3-iloxi)-cromen-2-ona, uso y equipo
BRPI0510503A (pt) compostos e composições como inibidores de catepsina s